ADC Therapeutics remains a Strong Buy with promising ZYNLONTA trials targeting lymphoma, data expected by 2026.

ADC Therapeutics SA is rated a Strong Buy due to its pivotal ZYNLONTA combination trials for second-line relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The phase 3 LOTIS-5 trial topline data, combining ZYNLONTA with rituximab, is anticipated in Q2 2026 and represents a key milestone. Additionally, the phase 1b LOTIS-7 trial combining ZYNLONTA with glofitamab has shown an 89.8% overall response rate and 77.6% complete response rate, with more data expected by the end of 2026. The company’s $231 million cash runway extends into 2028, reducing near-term dilution risk and supporting ongoing clinical development.